Skip to main content
SpringerLink
Log in

Calcipotriol Ointment

A Review of its Use in the Management of Psoriasis

  • Adis Drug Evaluation
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Abstract

Calcipotriol, a vitamin D3 analog, acts not only to inhibit cell proliferation and enhance cell differentiation in the skin of patients with psoriasis, but also appears to have effects on immunologic markers that are thought to play a role in the etiology of the disease.

In several well designed, short term studies in adults, calcipotriol ointment 50 μg/g twice daily provided similar or superior efficacy to several other antipsoriatic agents in adult patients with mild to moderate psoriasis. In patients with nonscalp psoriasis, the drug provided superior efficacy to twice daily placebo (vehicle ointment), twice daily fluocinonide 500 μg/g, once daily tacalcitol 4 μg/g and twice daily coal tar 5% plus allantoin 2% and hydrocortisone 0.5%. Furthermore, calcipotriol therapy generally provided superior efficacy to twice daily betamethasone valerate 1 to 1.2 mg/g or once daily dithranol 1 to 20 mg/g, and similar efficacy to twice daily betamethasone dipropionate plus salicylic acid or once daily maxacalcitol 6 to 50 μg/g. Limited data indicated that calcipotriol ointment 50 μg/g also improved overall disease severity in children.

In combination with other antipsoriatic agents [acitretin, cyclosporine, betamethasone valerate, halobetasol (ulobetasol)], ultraviolet B or psoralen ultraviolet A (PUVA) phototherapy, calcipotriol ointment 50 μg/g twice daily improved the beneficial effects of these drugs on overall disease severity in adult patients with moderate to severe psoriasis. Furthermore, in separate trials, calcipotriol combination therapy reduced the dosage of acitretin required to achieve clearance of psoriasis and the duration of PUVA and dosage of UVA phototherapy, potentially improving the benefit/risk ratio for these other antipsoriatic treatments.

Calcipotriol was generally well tolerated in short and long term studies in adult patients, with the majority of adverse events being mild to moderate in intensity and transient. The most common adverse events associated with calcipotriol therapy were dermatologic in nature and included lesional or perilesional irritations, face and scalp irritations, worsening of psoriasis and miscellaneous dermatologic events. Notably, there have been very few reports of patients developing hypercalcemia or hypercalciuria during calcipotriol therapy, with most occurring in patients who exceeded the recommended dosage of 100 g/week. Although data in children are limited, the drug was well tolerated with the nature and incidence of adverse effects similar to those observed in adult patients.

Conclusions: Extensive clinical experience, along with several short and long term clinical trials, has shown calcipotriol ointment to be an effective and well tolerated topical agent in adult patients with psoriasis. In addition, calcipotriol ointment proved beneficial in combination with other topical, phototherapy or systemic antipsoriatic treatments, reducing the dosage and/or duration of some of these treatments and potentially improving their benefit/risk ratio. Calcipotriol ointment is valuable as a first- or second-line therapy option for the management of mild to moderate psoriasis and in combination with other antipsoriatic agents for more severe psoriasis.

Pharmacologic Properties

Calcipotriol inhibits cell proliferation and enhances cell differentiation in the skin of patients with psoriasis. These effects are mediated by binding of the drug to vitamin D receptors. Flow cytometric analysis of epidermal samples has shown significant decreases relative to placebo in numbers of proliferating basal keratinocytes in psoriatic skin treated with topical calcitriol. In addition, application of calcipotriol ointment 50 μg/g twice daily for up to 8 weeks has been shown to result in partial recovery of the stratum corneum, restoration of the stratum granulosum, and correction of intercellular spacing and number and structure of desmosomes.

Application of calcipotriol ointment for 4 weeks has been associated with suppression of epidermal T cell and polymorphonuclear leucocyte accumulation in psoriatic lesions. The drug has also been shown to reduce numbers and activity of Langerhans cells, although these effects have not been shown consistently across studies and require further investigation. Other effects described include increased interleukin-10 and reduced interleukin- 8 expression, and normalization of cellular integrin distribution.

Overall, application of up to 120 g/week of calcipotriol ointment 50 μg/g did not alter calcium utilization or bone turnover in pharmacodynamic studies in humans. Dosages of 100 to 300 g/week have, however, been associated with increased levels of calcium and reduced levels of parathyroid hormone (PTH) in serum, and increased urinary excretion of calcium. These effects have been attributed to increased intestinal absorption of calcium and subsequent suppression of secretion of PTH and endogenous calcitriol.

Measurement of levels of radioactivity in blood, urine and feces after application of ointment containing 3H-calcipotriol has indicated systemic absorption of up to approximately 6% of applied drug in patients with psoriasis. Calcipotriol appears to be metabolized and cleared rapidly after absorption, with hepatic oxidation to 2 relatively inactive metabolites (MC1046 and MC1080) being the major route of elimination. Data obtained in rats showed elimination half-lives in blood collected up to 10 minutes after intravenous administration to be 4 and 14 minutes for calcipotriol and calcitriol, respectively. Corresponding total clearance values were 0.68 and 0.0055 L/h.

Clinical Efficacy

The short term clinical efficacy of calcipotriol ointment 50 μg/g twice daily has been evaluated in several reasonably sized (≥50 enrolled patients) comparative studies of ≤14 weeks duration in adult patients with psoriasis. In placebo (vehicle)-controlled studies, calcipotriol recipients experienced better reductions in overall disease severity (52 to 59% vs 16 to 35%), with a greater percentage of calcipotriol-treated patients achieving a ≥75% improvement in severity of psoriasis or complete clearance (responders) than placebo (59 to 74% vs 12 to 19%). Furthermore, topical calcipotriol ointment 50 μg/g twice daily provided superior efficacy to once daily tacalcitol 4 μg/g, twice daily fluocinonide 500 μg/g or twice daily coal tar 5% plus allantoin 2% and hydrocortisone 0.5% in patients with nonscalp psoriasis. In addition, calcipotriol recipients generally experienced superior beneficial effects on psoriasis severity to betamethasone valerate (1 to 1.2 mg/g twice daily) or once daily dithranol 1 to 20 mg/g recipients and similar efficacy to those receiving betamethasone dipropionate plus salicylic acid or once daily maxacalcitol 6 to 50 μg/g. Calcipotriol ointment also had significantly (p < 0.001) greater cosmetic acceptability than short-contact dithranol cream. Patient’s quality of life was significantly (p ≤ 0.02, both comparisons) improved from pretreatment levels with twice daily calcipotriol ointment 50 μg/g (assessed using Psoriasis Disease Index and Sickness Impact Profile instruments).

Long term evaluations indicated that improvements in disease severity demonstrated with calcipotriol ointment therapy in the short term were maintained throughout the study period in several noncomparative trials of up to 1 year in duration in adult patients with psoriasis. At the end of the treatment period, 54 to 98% of calcipotriol recipients had shown a marked or ≥75% improvement in severity of psoriasis in these trials. Furthermore, in a randomized double-blind study, significantly (p < 0.05) more recipients of combination ‘pulse therapy’ consisting of calcipotriol ointment 50 μg/g (applied twice daily on week days) plus halobetasol ointment 500 μg/g (applied twice daily during the weekend) remained in remission throughout the 6-month study period than halobetasol recipients (using the same dosage plus placebo ointment twice daily during the week) [76 vs 40%].

Combining topical calcipotriol ointment (50 μg/g) with a topical corticosteroid, ultraviolet B (UVB) phototherapy, psoralen ultraviolet A (PUVA) phototherapy, or systemic (cyclosporine, acitretin) antipsoriatic agents improved the effects of the individual agents in reducing overall disease severity in short term studies of 2 to 12 weeks’ duration in adults. Overall psoriasis severity scores were reduced by 74 to 91% with calcipotriol-combination therapy compared with reductions of 35 to 83% in comparator agent monotherapy groups. Importantly, the addition of calcipotriol to acitretin or PUVA phototherapy reduced the dosage of these antipsoriatic therapies required and duration of UVA phototherapy.

Data on the therapeutic efficacy of topical calcipotriol ointment in children are limited. After 8 weeks’ therapy, there was no significant difference in the reduction in overall disease severity between twice daily calcipotriol ointment 50 μg/g and placebo (ointment vehicle; 52 vs 37% reduction) in children aged 2 to 14 years. Nevertheless, subscale scores for erythema and scaling showed significantly (p < 0.05, both comparisons) greater reductions in calcipotriol than placebo recipients. In addition, significantly (p < 0.05) more calcipotriol recipients had shown a marked improvement or clearance of psoriasis than placebo (60 vs 44%). Topical calcipotriol ointment 50 μg/g twice daily also proved effective in reducing disease severity in a long term noncomparative study in 12 children aged 8 to 15 years. The mean overall Psoriasis Area and Severity Index score was reduced by 65% following calcipotriol treatment for a mean duration of 40 weeks.

Tolerability

In short term studies (6 to 8 weeks’ duration) the most common dermatologic adverse events associated with calcipotriol ointment 50 μg/g twice daily were lesional and perilesional irritation (12 to 20.1% of patients), face and scalp irritations (2 to 4.2%), worsening of psoriasis (2.9 to 3.9%) and miscellaneous adverse events (2.2 to 10.9%). The incidence of nondermatologic adverse events (e.g. arthralgias, bronchospasm, fatigue, flu-like symptoms, headache and nausea/vomiting) in these large trials was 1.2 to 2.9% of patients, with the overall incidence of adverse events ranging from 12 to 35.1% of patients. Symptoms were generally transient and mild to moderate in intensity. Zero to 10.2% of patients withdrew because of adverse events attributable to calcipotriol ointment treatment. The nature of adverse events occurring in long term studies was similar to those observed with short term studies, although the overall incidence of adverse events declined over time. Serious adverse events associated with calcipotriol therapy were rare.

Calcipotriol ointment 50 μg/g twice daily was better tolerated than dithranol, but was associated with a significantly (p < 0.001) higher incidence of lesional and perilesional irritation than betamethasone valerate treatment. Although no significant differences in the nature and incidence of adverse events were reported between calcipotriol ointment or tacalcitol treatment in patients with nonscalp psoriasis, in those with scalp psoriasis there was a trend to a higher incidence of facial irritations with calcipotriol than tacalcitol.

In general clinical practice, there have been very few reports of patients developing hypercalcemia or hypercalciuria during calcipotriol therapy, with most occurring in patients who exceeded the recommended dosage of 100 g/week. All episodes of hypercalcemia or hypercalciuria have resolved on discontinuation of treatment. Furthermore, there were no reports of any significant abnormalities in hematologic and biochemical laboratory parameters with twice daily calcipotriol ointment 50 μg/g in clinical trials.

Limited data from short term studies of 8 weeks’ duration indicated that calcipotriol ointment 50 μg/g twice daily was well tolerated in 99 children aged 2 to 15 years. No serious adverse events were reported. Adverse events were similar to those observed in adults. In a short term study, adverse events possibly or probably related to calcipotriol therapy were lesional and perilesional irritations (11 to 16% of patients), irritations of the face and/or scalp (5 to 6%), various skin rashes (6%) and worsening of psoriasis (2%). In addition, there were no significant changes in hematologic or biochemical laboratory parameters, including no clinically relevant changes in liver and renal function tests or serum calcium levels. Although data are very limited, a study in 12 children (aged 8 to 15 years) indicated that calcipotriol ointment 50 μg/g twice daily (for up to 106 weeks; mean duration of therapy was 40 weeks) was well tolerated with no serious adverse effects reported.

Dosage and Administration

Calcipotriol ointment 50 μg/g is approved for the treatment of moderate plaque psoriasis. It should be applied once or twice daily to the affected area up to a maximum of 100 g/week in adult patients. In Japan, the maximum recommended adult dosage is 90 g/week. Currently, in the US there are no dosage recommendations available for the use of calcipotriol in children, whereas in the UK the maximum recommended dosage in children aged 6 to 12 years is 50 g/week increasing to 75 g/week in those over 12 years of age; no dosage recommendations are available for children less than 6 years of age. Calcipotriol should not be applied to the face or eyes, and hands should be washed to prevent this happening inadvertently.

Calcipotriol is contraindicated in patients with known calcium metabolism disorders, evidence of vitamin D toxicity or hypersensitivity to calcipotriol or any other constituents of the ointment. The use of the drug during pregnancy is not recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Table II
Fig. 3
Fig. 4
Table III
Fig. 5
Table IV
Table V
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Gottlieb A.B. Psoriasis. Dis Manage Clin Outcomes 1998 Nov–Dec; 1: 195–202

    Article  Google Scholar 

  2. Nevitt G.J., Hutchinson P.E. Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards disease. Br J Dermatol 1996; 135: 533–537

    Article  PubMed  CAS  Google Scholar 

  3. Koo J. Therapeutic options for psoriasis: review and update. Saudi Med J 1998; 19 (3): 232–236

    Google Scholar 

  4. Gawkrodger D.J. Current management of psoriasis. Audit Subcommitee of the British Association of Dermatologists. J Dermatol Treat 1997; 8: 27–55

    Article  Google Scholar 

  5. Tan M.-H., Lebwohl M. Psoriasis. Drugs Today 1998 Jul; 34: 641–647

    Article  PubMed  CAS  Google Scholar 

  6. Greaves M.W., Weinstein G.D. Treatment of psoriasis. N Engl J Med 1995; 332 (9): 581–588

    Article  PubMed  CAS  Google Scholar 

  7. Dyke H.J., Montana J.G. The therapeutic potential of PDE4 inhibitors. Expert Opin Invest Drug 1999 Sep; 8: 1301–1325

    Article  CAS  Google Scholar 

  8. Bonifati C., Carducci M., Mussi A., et al. Recognition and treatment of psoriasis: special considerations in elderly patients. Drugs Aging 1998 Mar; 12: 177–190

    Article  PubMed  CAS  Google Scholar 

  9. Tsankov N., Angelova I., Kazandjieva J. Drug-induced psoriasis: recognition and management. Am J Clin Dermatol 2000 May-Jun; 1: 159–165

    Article  PubMed  CAS  Google Scholar 

  10. Henseler T., Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450–456

    Article  PubMed  CAS  Google Scholar 

  11. Murdoch D., Clissold S.P. Calcipotriol: a review of its pharmacological properties and therapeutic use in psoriasis vulgaris. Drugs 1992 Mar; 43: 415–429

    Article  PubMed  CAS  Google Scholar 

  12. Lea A.P., Goa K.L. Calcipotriol: a review of its pharmacological properties and therapeutic efficacy in the management of psoriasis. Clin Immunother 1996 Mar; 5: 230–248

    Article  Google Scholar 

  13. Berth-Jones J. The emergence of vitamin D as a first-line treatment for psoriasis. J Dermatol Treat 1998; 9 Suppl. 3: 13–18

    Article  Google Scholar 

  14. Morimoto S., Kumahara Y. A patient with psoriasis cured by 1a-hydroxyvitamin D3. Med J Osaka Univ 1985; 35: 51–54

    PubMed  CAS  Google Scholar 

  15. Hansen C.M., Mathiasen I.S., Binderup L. The anti-proliferative and differentiationinducing effects of vitamin D analogs are not determined by the binding affinity for the vitamin D receptor alone. J Invest Dermatol Symp Proc 1996 Apr; 1: 44–48

    CAS  Google Scholar 

  16. Berg J.P., Liane K.M., Bjørhovde S.B., et al. Vitamin D receptor binding and biological effects of cholecalciferol analogues in rat thyroid cells. J Steroid Biochem Mol Biol 1994; 50 (3/4): 145–150

    Article  PubMed  CAS  Google Scholar 

  17. Binderup L. Comparison of calcipotriol with selected metabolites and analogues of vitamin D3: effects on cell growth regulation in vitro and calcium metabolism in vivo. Pharmacol Toxicol 1993; 72: 240–244

    Article  PubMed  CAS  Google Scholar 

  18. Binderup L., Bramm E. Effects of a novel vitamin D analogue MC 903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 1988; 37 (5): 889–895

    Article  PubMed  CAS  Google Scholar 

  19. Reichrath J, Müller S.M., Kerber A., et al. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 1997 Jan; 36: 19–28

    Article  PubMed  CAS  Google Scholar 

  20. Glade C.P., Van Erp P.E., Van Hooijdonk C.A., et al. Topical treatment of psoriatic plaques with 1-α 24 dihydroxyvitamin D3: a multiparameter flow cytometrical analysis of epidermal growth, differentiation and inflammation. Acta Derm Venereol 1995 Sep; 75: 381–385

    PubMed  CAS  Google Scholar 

  21. Palleschi G.M., Gentili A., Caproni M., et al. Structural alterations of basal keratinocytes and capillary loop in psoriasis during treatment with topical calcipotriol. Acta Derm Venereol (Stock) 1994; 186 Suppl.: 49–51

    CAS  Google Scholar 

  22. Van Der Vleuten C.J.M., De Jong E., Van De Kerkhof P.C.M. Epidermal differentiation characteristics of the psoriatic plaque during treatment with calcipotriol. Arch Dermatol Res 1996 Jun; 288: 366–372

    Article  PubMed  Google Scholar 

  23. Cavicchini S., Brezzi A., Gasparini G., et al. Skin ultrastructure after calcipotriol treatment: a transmission electron microscopic and freeze-fracture study on psoriatic patients. Acta Derm Venereol 1996 May; 76: 186–189

    PubMed  CAS  Google Scholar 

  24. Rollman O., Törmä H., Pihl-Lundin I., et al. The effect of topical calcipotriol on vitamin A concentrations in normal and psoriatic skin [abstract]. J Invest Dermatol Symp Proc 1996 Apr; 1: 109

    Google Scholar 

  25. Kim S.E., Heickendorff L., Bjerring P., et al. Metabolism of collagens type I and type III in normal skin after application of calcipotriol: stimulation of collagen synthesis but potentiation of the corticosteroid-induced inhibition of collagen synthesis [abstract]. J Invest Dermatol Symp Proc 1996 Apr; 1: 106

    Google Scholar 

  26. Dam T.N., Møller B., Hindkjaer J., et al. The vitamin D3 analog calcipotriol suppresses the number and antigen-presenting function of Langerhans cells in normal human skin. J Invest Dermatol Symp Proc 1996 Apr; 1: 72–77

    CAS  Google Scholar 

  27. Jensen A.M., Lladø M.B., Skov L., et al. Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol 1998 Dec; 139: 984–991

    Article  PubMed  CAS  Google Scholar 

  28. Savoia P., Novelli M., De Matteis A., et al. Effects of topical calcipotriol on the expression of adhesion molecules in psoriasis [abstract]. J Invest Dermatol 1997 Sep; 109: 464

    Google Scholar 

  29. Berth-Jones J., Fletcher A., Hutchinson P.E. Epidermal cytokeratin and immunocyte responses during treatment of psoriasis with calcipotriol and betamethasone valerate. Br J Dermatol 1992; 126: 356–361

    Article  PubMed  CAS  Google Scholar 

  30. Mozzanica N., Cattaneo A., Schmitt E., et al. Topical calcipotriol for psoriasis: an immunohistologic study. Acta Derm Venereol (Stock) 1994; 186 Suppl.: 171–172

    CAS  Google Scholar 

  31. Finzi A.F. A controlled, multicentre study comparing the efficacy and safety of calcipotriol with a combination of betamethasone dipropionate/salicylic acid [abstract]. Satellite Symposium of the Third Congress of the European Academy of Dermatology and Venereology; 1993 Sep; Copenhagen

  32. Kang S., Yi S., Griffiths C.E., et al. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 1998 Jan; 138: 77–83

    Article  PubMed  CAS  Google Scholar 

  33. Cagnoni M.L., Ghersetich I., Lotti T., et al. Treatment of psoriasis vulgaris with topical calcipotriol: is the clinical improvement of lesional skin related to a down-regulation of some cell adhesion molecules. Acta Derm Venereol 1994 Suppl. 186: 55–57

    CAS  Google Scholar 

  34. Michel G., Gailis A., Jarzebska-Deussen B., et al. 1,25-(OH)2-vitamin D3 and calcipotriol induce IL-10 receptor gene expression in human epidermal cells. Inflamm Res 1997 Jan; 46: 32–34

    Article  PubMed  CAS  Google Scholar 

  35. Muller K., Svenson M., Bendtzen K. 1α,25 dihydroxyvitamin D3 and a novel vitamin D analogue MC 903 are potent inhibitors of human interleukin 1 in vitro. Immunol Lett 1988; 17: 361–366

    Article  PubMed  CAS  Google Scholar 

  36. Müller K., Diamant M., Bendtzen K. Inhibition of production and function of interleukin- 6 by 1,25-dihydroxyvitamin D3. Immunol Lett 1991; 28: 115–120

    Article  PubMed  Google Scholar 

  37. Kemény L, Kenderessy A.S., Olasz E., et al. The interleukin-8 receptor: a potential target for antipsoriatic therapy? Eur J Pharmacol 1994; 258: 269–272

    Article  PubMed  Google Scholar 

  38. Bouillon R., Allewaert K., Xiang D.Z., et al. Vitamin D analogs with low affinity for the vitamin D binding protein: enhanced in vitro and decreased in vivo activity. J Bone Miner Res 1991; 6 (10): 1051–1057

    Article  PubMed  CAS  Google Scholar 

  39. Mortensen L., Kragballe K., Wegmann E., et al. Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism: a randomized, double-blind, placebo-controlled study. Acta Derm Venereol 1993 Aug; 73: 300–304

    PubMed  CAS  Google Scholar 

  40. Guzzo C., Lazarus G., Goffe B.S., et al. Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis. J Am Acad Dermatol 1996 Mar; 34: 429–433

    Article  PubMed  CAS  Google Scholar 

  41. Bourke J.F., Berth-Jones J., Elouzi H., et al. A single topical application of calcipotriol (50 micrograms/g) ointment has no acute effect on systemic calcium homeostasis in patients with chronic plaque psoriasis [letter]. Clin Exp Dermatol 1996 Jul; 21: 320–321

    Article  PubMed  CAS  Google Scholar 

  42. Azuma J., Hamaguchi T., Iwasa M., et al. Study on safety and pharmacokinetics of MC903 ointment in normal volunteers: phase I study [in Japanese]. Rinsho Iyaku 1995; 11 (11): 2341–2366

    Google Scholar 

  43. Berth-Jones J., Bourke J.F., Iqbal S.J., et al. Urine calcium excretion during treatment of psoriasis with topical calcipotriol. Br J Dermatol 1993 Oct; 129: 411–414

    Article  PubMed  CAS  Google Scholar 

  44. Bourke J.F., Berth-Jones J., Mumford R., et al. High dose topical calcipotriol consistently reduces serum parathyroid hormone levels. Clin Endocrinol Oxf 1994 Sep; 41: 295–297

    Article  PubMed  CAS  Google Scholar 

  45. Bourke J.F., Mumford R., Whittaker P., et al. The effects of topical calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis. J Am Acad Dermatol 1997 Dec; 37: 929–934

    Article  PubMed  CAS  Google Scholar 

  46. Bourke J.F., Iqbal S.J., Hutchinson P.E. The effects of UVB plus calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis. Clin Exp Dermatol 1997 Nov; 22: 259–261

    Article  PubMed  CAS  Google Scholar 

  47. American Society of Hospital Pharmacists Calcipotriene. In: McEvoy G.K., editor. AHFS Drug Information. Bethesda (MO): Datapharma Publication Limited, 2000: 3253

    Google Scholar 

  48. Liao W.-c., Kripalani K., Natarajan C., et al. Percutaneous absorption of 3Hcalcipotriene ointment in healthy male volunteers and male psoriatic patients [abstract]. Clin Res 1993 Apr; 41: 497A

    Google Scholar 

  49. Delaney C., Liao W., Cohen M., et al. Percutaneous absorption of calcipotriene (calcipotriol) in normal volunteers and psoriatic patients after a single dose of 3H-calcipotriene and in psoriatic patients after a single dose of 3H-calcipotriene following multiple dose treatment with non-radiolabeled calcipotriene 0.005 % ointment [abstract]. J Invest Dermatol Symp Proc 1996 Apr; 1: 112

    Google Scholar 

  50. Rougier A., Lotte C., Maibach H.I. In vivo percutaneous penetration of some organic compounds related to anatomic site in humans: predictive assessment by the stripping method. J Pharm Sci 1987; 76 (6): 451–454

    Article  PubMed  CAS  Google Scholar 

  51. Yoshikawa K., Nomura M., Higashiyama M., et al. Clinical pharmacological study on MC903 ointment: pharmacokinetic investigation in patients with psoriasis vulgaris [in Japanese]. Rinsho Iyaku 1995; 11 (11): 2379–2389

    Google Scholar 

  52. Kissmeyer A.-M., Binderup L. Calcipotriol (MC903): pharmacokinetics in rats and biological activities of metabolites. Biochem Pharmacol 1991; 41 (11): 1601–1606

    Article  PubMed  CAS  Google Scholar 

  53. Sørensen H., Binderup L., Calverley M,., et al. In vitro metabolism of calcipotriol (MC 903), a vitamin D analogue. Biochem Pharmacol 1990; 39 (2): 391–393

    Article  PubMed  Google Scholar 

  54. Masuda S., Strugnell S., Calverley M.J., et al. In vitro metabolism of the anti-psoriatic vitamin D analog, calcipotriol, in two cultured human keratinocyte models. J Biol Chem 1994; 269 (7): 4794–4803

    PubMed  CAS  Google Scholar 

  55. Dubertret L., Wallach D., Souteyrand P., et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris: a randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 1992 Dec; 27 (6 Pt 1): 983–988

    Article  PubMed  CAS  Google Scholar 

  56. Highton A., Quell J. Calcipotriene ointment 0.005 % for psoriasis: a safety and efficacy study. Calcipotriene Study Group. J Am Acad Dermatol 1995 Jan; 32: 67–72

    Article  PubMed  CAS  Google Scholar 

  57. Pariser D.M., Pariser R.J., Breneman D., et al. Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebo-controlled study [letter]. Arch Dermatol 1996 Dec; 132: 1527

    Article  PubMed  CAS  Google Scholar 

  58. Barker J.N.W.N., Ashton R.E., Marks R., et al. Topical maxacalcitol for the treatment of psoriasis vulgaris:a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 1999; 141: 274–278

    Article  PubMed  CAS  Google Scholar 

  59. Langner A., Stapør W., Ambroziak M. Vitamin D3 metabolites and analogues in the treatment of scalp psoriasis. J Dermatol Treat 1998; 9 Suppl. 3: S41–S45

    Article  CAS  Google Scholar 

  60. Veien N.K., Bjerke J.R., Rossmann-Ringdahl I., et al. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol 1997 Oct; 137: 581–586

    Article  PubMed  CAS  Google Scholar 

  61. Bruce S., Epinette W.W., Funicella T., et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994 Nov; 31 (5 Pt 1): 755–759

    Article  PubMed  CAS  Google Scholar 

  62. Cunliffe W.J., Berth-Jones J., Claudy A., et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992 May; 26 (5 Pt 1): 736–743

    Article  PubMed  CAS  Google Scholar 

  63. Kragballe K., Gjertsen B.T., De Hoop D., et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris [published erratum appears in Lancet 1991 Apr 20;337 (8747):988] [see comments]. Lancet 1991 Jan 26; 337: 193–196

    Article  PubMed  CAS  Google Scholar 

  64. Vladimirov V.V., Tcherjomukchina I.G., Kurjanova O.N., et al. Efficacy of calcipotriol ointment compared to betamethasone 17-valerate ointment in the treatment of psoriasis [abstract]. International Meeting Skin Therapy Update 1994; Crete; 219

  65. Berth-Jones J., Chu A.C., Dodd W.A., et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992 Sep; 127: 266–271

    Article  PubMed  CAS  Google Scholar 

  66. Christensen O.B., Mørk N.-J., Ashton R., et al. Comparison of a treatment phase and a follow-up phase of short-contact dithranol and calcipotriol in outpatients with chronic plaque psoriasis. J Dermatol Treat 1999; 10 (4): 261–265

    Article  CAS  Google Scholar 

  67. Pinheiro N. Comparative effects of calcipotriol ointment (50 μg/g) and 5% coal tar/2% allantoin/0.5 % hydrocortisone cream in treating plaque psoriasis. Br J Clin Pract 1997; 51: 16–19

    PubMed  CAS  Google Scholar 

  68. Wall A.R., Poyner T.F., Menday A.P. A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis. Br J Dermatol 1998 Dec; 139: 1005–1011

    Article  PubMed  CAS  Google Scholar 

  69. Zonneveld I.M., Rubins A., Jablonska S., et al. Topical tacrolimus is not effective in chronic plaque psoriasis: a pilot study [published erratum appears in Arch Dermatol 1998 Nov; 134 (11): 1386]. Arch Dermatol 1998 Sep; 134: 1101–1102

    Article  PubMed  CAS  Google Scholar 

  70. Ohgawara A., Kobayashi h., Iizuka H., et al. Clinical evaluation of MC903 (calipotriol) ointment in patients with psoriasis vulgaris: a right to left comparative study against betamethasone valerate ointment (phase III study) [in Japanese]. Rinsho Iyaku 1995; 11 (12): 2573–2587

    Google Scholar 

  71. Crosti C., Finzi A.B., Mian E., et al. Calcipotriol in psoriasis vulgaris: a controlled trial comparing betamethasone dipropiante + salicylic acid. Int J Dermatol 1997; 36: 537–541

    Article  PubMed  CAS  Google Scholar 

  72. Guenther L.C., Poulin Y.P., Pariser D.M. A comparison of tazarotene 0.1 % gel once daily plus mometasone furoate 0.1 % cream once daily versus calcpotriene 0.0 05 % ointment twice daily in the treatment of plaque psoriasis. Clin Ther 2000; 22 (10): 1225–1238

    Article  PubMed  CAS  Google Scholar 

  73. Georgala S., Avgerinou G., Gourigiotou K., et al. The effect of calcipotriol ointment in psoriasis vulgaris [abstract]. International Meeting Skin Therapy Update 1994; Crete; 221

  74. Bourke J.F., Berth-Jones J., Iqbal S.J., et al. High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br J Dermatol 1993 Jul; 129: 74–76

    Article  PubMed  CAS  Google Scholar 

  75. Kienbaum S., Lehmann P., Ruzicka T. Topical calcipotriol in the treatment of intertriginous psoriasis. Br J Dermatol 1996 Oct; 135: 647–650

    Article  PubMed  CAS  Google Scholar 

  76. Kose O. 5 and 10 days occlusive treatment with calcipotriol ointment in scalp psoriasis [abstract]. J Eur Acad Dermatol Venereol 1995 Oct; 5 Suppl. 1: S148

    Article  Google Scholar 

  77. Osborne G.E.N., Roberts N.M. Chronic plaque psoriasis — achieving clearance with calcipotriol ointment [abstract no.466]. 57th Annual Meeting of the American Academy of Dermatology; 1999 19 Mar, New Orleans

  78. V’azquez-L’opez F., Pérez-Oliva N., Hernandez-Mejia R. Topical calcipotriene ointment and etretinate: another combination therapy for psoriasis vulgaris [letter; comment]. J Am Acad Dermatol 1997 May; 36 (5 Pt 1): 803

    Article  Google Scholar 

  79. Tanghetti E.A. An open-label photographic and clinical study evaluating the effect of adding mometasone furoate 0.1 % cream or calcipotriene ointment to tazarotene therapy in patients with mild-to-moderate plaque psoriasis [abstract no. 474]. 57th Annual Meeting of the American Academy of Dermatology; 1999 19 Mar; New Orleans

  80. Speight E.L., Farr P.M. Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol 1994 Jan; 130: 79–82

    Article  PubMed  CAS  Google Scholar 

  81. Singh S., Reddy D.C.S., Pandey S.S. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks. J Am Acad Dermatol 2000 Jul; 43 (1 Pt 1): 61–65

    Article  PubMed  CAS  Google Scholar 

  82. Remitz A., Reitamo S., Erkko P., et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999 Jul; 141: 103–107

    Article  PubMed  CAS  Google Scholar 

  83. Kokelj F., Lavaroni G., Guadagnini A. UVB versus UVB plus calcipotriol (MC 903) therapy for psoriasis vulgaris. Acta Derm Venereol 1995 Sep; 75: 386–387

    PubMed  CAS  Google Scholar 

  84. Dutz J.P., Lui H. A comparative study of calcipotriol and anthralin for chronic plaque psoriasis in a day care treatment center. Int J Dermatol 1998 Jan; 37: 51–53

    Article  PubMed  CAS  Google Scholar 

  85. Hecker D., Lebwohl M. Topical calcipotriene in combination with UVB phototherapy for psoriasis. Int J Dermatol 1997 Apr; 36: 302–303

    Article  PubMed  CAS  Google Scholar 

  86. Kragballe K., Fogh K., Søgaard H. Long-term efficacy and tolerability of topical calcipotriol in psoriasis: results of an open study. Acta Derm Venereol 1991; 71: 475–478

    PubMed  CAS  Google Scholar 

  87. Kose O. Calcipotriol ointment vs clobetasol solution in scalp psoriasis [letter]. J Dermatol Treat 1997; 8 (4): 287

    Article  Google Scholar 

  88. Bjerke J.R., Austad J. Clobetasol propionate ointment followed by calcipotriol ointment alone in the treatment of psoriasis [abstract]. Br J Dermatol 1996 Nov; 135: 848

    Google Scholar 

  89. Tham S.N., Lun K.C., Cheong W.K. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994 Nov; 131: 673–677

    Article  PubMed  CAS  Google Scholar 

  90. Grattan C.E.H., Hallam F., Whitefield M. A new aqueous dithranol gel for psoriasis: comparison with placebo and calcipotriol ointment. J Dermatol Treat 1997; 8 (1): 11–15

    Article  Google Scholar 

  91. Bourke J.F., Iqbal S.J., Hutchinson P.E. A randomized double-blind comparison of the effects on systemic calcium homeostasis of topical calcitriol (3 μg/g) and calcipotriol (50 μg/g) in the treatment of chronic plaque psoriasis vulgaris. Acta Derm Venereol 1997 May; 77: 228–230

    PubMed  CAS  Google Scholar 

  92. Hartmann I. Combination of ointment Daivonex and UVB radiation for the treatment of psoriasis [abstract]. Journal of the European Academy of Dermatology and Venereology 1996 Oct; 7 Suppl. 2: S190–S191

    Article  Google Scholar 

  93. Kokelj F., Torsello P., Plozzer C. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 1998 Mar; 10: 143–146

    Article  PubMed  CAS  Google Scholar 

  94. Austad J., Bjerke J.R., Gjertsen B.T., et al. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. J Eur Acad Dermatol Venereol 1998 Jul; 11: 19–24

    Article  PubMed  CAS  Google Scholar 

  95. Colombo R., Soltani S. Short-term treatment with calcipotriol in chronic psoriasis [in Italian]. Giornale Italiano di Dermatologia e Venereologia 1997; 133 (6): 459–463

    Google Scholar 

  96. Brands S., Brakman M., Bos J.D., et al. No additional effect of calcipotriol ointment on low-dose narrow-band UVB phototherapy in psoriasis. J Am Acad Dermatol 1999 Dec; 41: 991–995

    Article  PubMed  CAS  Google Scholar 

  97. Frappaz A., Thivolet J. Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis. Eur J Dermatol 1993; 3: 351–354

    Google Scholar 

  98. Grossman R.M., Thivolet J., Claudy A., et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994 Jul; 31: 68–74

    Article  PubMed  CAS  Google Scholar 

  99. Lebwohl M., Siskin S.B., Epinette W., et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996 Aug; 35 (2 Pt 1): 268–269

    Article  PubMed  CAS  Google Scholar 

  100. Molin L. Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. Dermatology 1999; 198: 375–381

    Article  PubMed  CAS  Google Scholar 

  101. Picot E., Beani J.C., Cambazard F., et al. A comparative study of calcipotriol ointment in combination with narrow-band UVB TL-01 phototherapy, placebo controlled, in the treatment of psoriasis vulgaris [abstract no. 468]. 57th Annual Meeting of the American Academy of Dermatology; 1999 19 Mar: New Orleans

  102. Van De Kerkhof P.C., Cambazard F., Hutchinson P.E., et al. The effect of addition of calcipotriol ointment (50 μg/g) to acitretin therapy in psoriasis. Br J Dermatol 1998 Jan; 138: 84–89

    Article  PubMed  Google Scholar 

  103. Ruzicka T., Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks’ treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, doubleblind, randomized study. Br J Dermatol 1998; 138: 254–258

    Article  PubMed  CAS  Google Scholar 

  104. Youn J.-L., Park B.-S., Park S.-B., et al. Comparison of calcipotriol-PUVA with conventional PUVA in the treatment of psoriasis. J Dermatol Treat 2000; 11: 125–130

    Article  CAS  Google Scholar 

  105. Cullen S.I., Calcipotriene Study Group. Long-term effectiveness and safety of topical calcipotriene for psoriasis. Calcipotriene Study Group. South Med J 1996 Nov; 89: 1053–1056

    Article  PubMed  CAS  Google Scholar 

  106. Ellis J.P., Griffiths W.A.D., Klaber M.R. Long-term treatment of chronic plaque psoriasis with calcipotriol ointment in patients unresponsive to short-contact dithranol. Eur J Clin Res 1995; 7: 247–257

    Google Scholar 

  107. Ohgawara A., Kobayashi H., Tagami H., et al. Long-term treatment with MC903 (calcipotriol) ointment in patients with psoriasis vulgaris: an open clinical trial [in In Japanese]. Rinsho Iyaku 1995; 11 (12): 2589–2607

    Google Scholar 

  108. Poyner T., Hughes I.W., Dass B.K., et al. Long-term treatment of chronic plaque psoriasis with calcipotriol. J Dermatol Treat 1993; 4: 173–177

    Article  Google Scholar 

  109. Ramsay C.A., Berth-Jones J., Brundin G., et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994; 189: 260–264

    Article  PubMed  CAS  Google Scholar 

  110. Darley C.R., Cunliffe W.J., Green C.M., et al. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol 1996 Sep; 135: 390–393

    Article  PubMed  CAS  Google Scholar 

  111. Park S.B., Suh D.H., Youn J.I. A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis. Pediatr Dermatol 1999 Jul–Aug; 16: 321–325

    Article  PubMed  CAS  Google Scholar 

  112. Oranje A.P., Marcoux D., Svensson A., et al. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol 1997 Feb; 36 (2 Pt 1): 203–208

    Article  PubMed  CAS  Google Scholar 

  113. Marks R., Barton S., Shuttleworth D., et al. Assessment of disease progress in psoriasis. Arch Dermatol 1989; 125: 235–240

    Article  PubMed  CAS  Google Scholar 

  114. Exum M.L., Rapp S.R., Feldman S.R., et al. Measuring severity of psoriasis: methodological issues. J Dermatol Treat 1996; 7: 119–124

    Article  Google Scholar 

  115. Ashcroft D.M., Li Wan Po A., Williams H.C., et al. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141: 185–191

    Article  PubMed  CAS  Google Scholar 

  116. Marks R. Measurement of the response to treatment in psoriasis. J Dermatol Treat 1996; 7 Suppl. 1: S7–S10

    Article  Google Scholar 

  117. Fredriksson T., Lassus A., Salde L. Reproducibility of clinical trials of topical glucocorticosteroids. Int J Dermatol 1983; 22: 536–539

    Article  PubMed  CAS  Google Scholar 

  118. Lebwohl M., Yoles A., Lombardi K., et al. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 1998 Sep; 39: 447–450

    Article  PubMed  CAS  Google Scholar 

  119. Giannotti B., Carli P., Varotti C., et al. treatment of psoriasis with calcipotriol: time of onset and healing relapses. Eur J Dermatol 1997; 7: 275–278

    CAS  Google Scholar 

  120. Bergner M., Bobbitt R.A., Carter W.B., et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787–805

    Article  PubMed  CAS  Google Scholar 

  121. Ashcroft D.M., Li Wan Po A., Williams H.C., et al. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther 1998; 23: 391–398

    Article  PubMed  CAS  Google Scholar 

  122. Finlay A.Y., Khan G.K., Luscombe D.K., et al. Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis. Br J Dermatol 1990; 123: 751–756

    Article  PubMed  CAS  Google Scholar 

  123. Baiocchi R., Bertani E., Biggio P., et al. Controlled trial of the efficacy and safety of calcipotriol ointment applied once or twice daily in psoriasis vulgaris [in Italian]. Giornale Italiano di Dermatologia e Venereologia 1996; 132 (2): 139–147

    Google Scholar 

  124. Tosti A., Piraccini B.M., Cameli N., et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998 Oct; 139: 655–659

    Article  PubMed  CAS  Google Scholar 

  125. Lambert J.R.M.G. Cost-effectiveness of treatments in psoriasis. J Dermatol Treat 1999 Mar; 10 Suppl. 1: S9–S13

    Google Scholar 

  126. Cork M. Economic considerations in the treatment of psoriasis. Dermatol Pract 1993; 1: 16–20

    Google Scholar 

  127. Harrington C.I. Cost-effectiveness analysis of calcipotriol ointment and ‘shortcontact’ dithranol in treating mild-to-moderate psoriasis. Br J Med Econ 1995; 8: 27–32

    Google Scholar 

  128. Katz H.I. Combined topical calcipotriene ointment 0.005 % and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists. J Am Acad Dermatol 1997 Sep; 37 (3 Pt 2): S62–S68

    Article  PubMed  CAS  Google Scholar 

  129. Gumowski-Sunek D., Rizzoli R., Saurat J.-H. Effects of topical calcipotriol on calcium metabolism in psoriatic patients: comparison with oral calcitriol. Dermatologica 1991; 183: 275–279

    Article  PubMed  CAS  Google Scholar 

  130. Berth-Jones J., Bourke J.F., Elouzi H., et al. Immediate and long term effects of topical calcipotriol on calcium homeostasis during treatment of psoriasis. Br J Dermatol 1992; 127 Suppl. 40: 17–18

    Google Scholar 

  131. Saurat J.-H., Gumowski-Sunek D., Rizzoli R. Topical calcipotriol and hypercalcaemia [letter]. Lancet 1991; 337: 1287

    Article  Google Scholar 

  132. Gumowski-Sunek D., Rizzoli R., Saurat J.-H. Calcium tolerance test in patients with extended body surface psoriasis and treated with calcipotriol. Dermatology 1992; 185 (3): 229–230

    Google Scholar 

  133. Russell S., Young M.J. Hypercalcaemia during treatment of psoriasis with calcipotriol. Br J Dermatol 1999; 130: 795

    Article  Google Scholar 

  134. Hardman K., Heath A., Nelson H.M. Hypercalcaemia associated with calcipotriol (Dononex) treatment. BMJ 1993; 306: 896

    Article  PubMed  CAS  Google Scholar 

  135. Kragballe K. Safety aspects of calcipotriol [abstract]. Acta Dermatol Venereol (Stockh) 1994; 186 Suppl.: 44

    Google Scholar 

  136. Dwyer C., Chapman R.S. Calcipotriol and hypercalcaemia [Letter]. Lancet 1991; 338: 764–765

    Article  PubMed  CAS  Google Scholar 

  137. Hoeck H.C., Laurberg G., Laurberg P. Hypercalcaemic crisis after excessive topical use of a vitamin D derivative. J Intern Med 1994; 235: 281–282

    Article  PubMed  CAS  Google Scholar 

  138. Dovonex ointment (calcipotriol). Curr Probl Pharmacovig 1994 Feb; 20: 3

    Google Scholar 

  139. Calcipotriol ointment for plaque psoriasis. Drug Ther Bull 1992 Mar 2; 30: 17-8

  140. McKenna K., Burrows D. Hypercalciuria and topical calcipotriol therapy. Br J Dermatol 1994; 131: 588

    Article  PubMed  CAS  Google Scholar 

  141. Bruynzeel D.P., Hol C.W., Nieboer C. Allergic contact dermatitis to calcipotriol [letter]. Br J Dermatol 1992; 127: 66

    Article  PubMed  CAS  Google Scholar 

  142. Yip J., Goodfield M. Contact dermatitis from MC 903, a topical vitamin D3 analogue. Contact Dermatitis 1991; 25: 139

    Article  PubMed  CAS  Google Scholar 

  143. De Groot A.C. Contact allergy to calcipotriol. Contact Dermatitis 1994; 30: 242–243

    Article  PubMed  Google Scholar 

  144. Steinkjer B. Contact dermatitis from calcipotriol. Contact Dermatitis 1994; 31 (2): 122

    Article  PubMed  CAS  Google Scholar 

  145. Serup J., Fullerton A., Vejlstrup E., et al. Suspected allergy to topical D-vitamin (Calcipotriol), guidance to patch testing [abstract]. Journal of the European Academy of Dermatology and Venereology 1996 Oct; 7 Suppl. 2: 110

    Google Scholar 

  146. Frosch P.J., Rustemeyer T. Contact allergy to calcipotriol does exist. Report of an unequivocal case and review of the literature. Contact Dermatitis 1999 Feb; 40: 66–71

    Article  PubMed  CAS  Google Scholar 

  147. McKenna K.E., Stern R.S. Photosensitivity associated with combined UV-B and calcipotriene therapy [see comments]. Arch Dermatol 1995 Nov; 131: 1305–1307

    Article  PubMed  CAS  Google Scholar 

  148. Kokelj F., Lavaroni G., Perkan V., et al. Hyperpigmentation due to calcipotriol (MC 903) plus heliotherapy in psoriatic patients: three case reports [see comments]. Acta Derm Venereol 1995 Jul; 75: 307–309

    PubMed  CAS  Google Scholar 

  149. Glaser R., Rowert J., Mrowietz U. Hyperpigmentation due to topical calcipotriol and photochemotherapy in two psoriatic patients. Br J Dermatol 1998 Jul; 139: 148–151

    Article  PubMed  CAS  Google Scholar 

  150. Dovonex Dovonex In: Physician’s Desk Reference. 54th ed. Montvale, NJ: Medical Economics, 2000: 3195

    Google Scholar 

  151. Fujisawa. Dononex ointment prescribing information. Fujisawa, Japan

  152. Royal Pharmaceutical Society of London. Preparations for psoriasis: calcipotriol. British National Formulary. Sep 2000 ed. v. 40. London: The Pharmaceutical Press, 2000: 522–523

    Google Scholar 

  153. Koo J., Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999 Jul; 41: 51–59

    Article  PubMed  CAS  Google Scholar 

  154. Van De Kerkhof P.C., De Hoop D., De Korte J., et al. Scalp psoriasis, clinical presentations and therapeutic management [published erratum appears in Dermatology 1999;198 (2):222]. Dermatology 1998; 197: 326–334

    Article  PubMed  Google Scholar 

  155. Finlay A.Y., Coles E.C. The effect of severe psoriasis on patient quality of life of 369 patients. Br J Dermatol 1995; 132: 236–244

    Article  PubMed  CAS  Google Scholar 

  156. Ramsay B., O’Reagan M. A survey of social and psychological effects of psoriasis. Br J Dermatol 1988; 118: 195–201

    Article  PubMed  CAS  Google Scholar 

  157. Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 1999; 38 (1): 16–24

    Article  PubMed  CAS  Google Scholar 

  158. Finzi A.F. The modern approach: new combined treatments for psoriasis. Acta Derm Venereol 1994 Suppl. 186: 105–106

    CAS  Google Scholar 

  159. van-de-Kerkhof P.C., Steegers-Theunissen R.P., Kuipers M.V. Evaluation of topical drug treatment in psoriasis. Dermatology 1998; 197: 31–36

    Article  PubMed  CAS  Google Scholar 

  160. Lebwohl M., Ellis C., Gottlieb A., et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998 Sep; 39: 464–475

    Article  PubMed  CAS  Google Scholar 

  161. Kuijpers A.L.A., Van De Kerkhof P.C.M. Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clin Dermatol 2000 Jan–Feb; 1: 27–39

    Article  PubMed  CAS  Google Scholar 

  162. Gasparro F.P. The role of PUVA in the treatment of psoriasis: photobiology issues related to skin cancer incidence. Am J Clin Dermatol 2000 Nov–Dec; 1: 337–348

    Article  PubMed  CAS  Google Scholar 

  163. Momtaz K.-T., Fitzpatrick T.B. Modifications of PUVA. Dermatol Clin 1995 Oct; 13: 867–873

    Google Scholar 

  164. Ashcroft D.M., Li Wan Po A., Williams H.C., et al. Combination regimens of topical calcipotriene in chronic plaque psoriasis. Arch Dermatol 2000; 136: 1536–1543

    Article  PubMed  CAS  Google Scholar 

  165. Koo J., Liao W. Update on psoriasis therapy: a perspective from the USA. Keio J Med 2000; 49 (1): 20–25

    Article  PubMed  CAS  Google Scholar 

  166. Koo J. How and why to use sequential therapy of psoriasis. Skin Aging 1998; 6: 42–46

    Google Scholar 

  167. Koo J.Y.M. Current consensus and update on psoriasis therapy: a perspective from the US. J Dermatol 1999; 26 (11): 723–733

    PubMed  CAS  Google Scholar 

  168. Guilhou J.J. The therapeutic effects of vitamin D3 and its analogues in psoriasis. Expert Opin Invest Drug 1998 Jan; 7: 77–84

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Inc., 860 Town Center Drive, Langhorne, Pennsylvania, 19047, USA

    Lesley J. Scott, Christopher J. Dunn & Karen L. Goa

Authors
  1. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher J. Dunn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karen L. Goa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley J. Scott.

Additional information

Various sections of the manuscript reviewed by: V. Aggarwal, Auckland, New Zealand; M. Berg, Department of Dermatology, Mälar Hospital, Eskilstuna, Sweden; J. Faergemann, Department of Dermatology and Venereology, Sahlgrenska University Hospital, Gothenburg, Sweden; A.B. Fleischer, Department of Dermatology, Wake Forest University, School of Medicine, Winston, Salem, North Carolina, USA; M. Lebwohl, Division of Clinical Dermatology, Mt. Sinai School of Medicine, New York, New York, USA; K. Yoshikawa, Department of Dermatology, Osaka University, Osaka, Japan.

Data Selection

Sources: Medical literature published in any language since 1980 on Calcipotriol, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International, Auckland, New Zealand). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: Medline search terms were ‘Calcipotriol’ or ‘Calcipotriene’ or ‘MC 903’ and ‘ointment’. EMBASE search terms were ‘Calcipotriol’ or ‘Calcipotriene’ or ‘MC 903’ and ‘ointment’. AdisBase search terms were ‘Calcipotriol’ or ‘Calcipotriene’ or ‘MC 903’ and ‘ointment’. Searches were last updated 19 Jan 2001.

Selection: Studies in patients with psoriasis who received calcipotriol ointment. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Calcipotriol, psoriasis, pharmacodynamics, pharmacokinetics, therapeutic use.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott, L.J., Dunn, C.J. & Goa, K.L. Calcipotriol Ointment. Am J Clin Dermatol 2, 95–120 (2001). https://doi.org/10.2165/00128071-200102020-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200102020-00008

Keywords

Search

Navigation